Form 4: Rocket Pharmaceuticals COO Receives Stock Grant
Insider Transaction (Form 4)
Christopher James Stevens, Chief Operating Officer of Rocket Pharmaceuticals, Inc., reported multiple transactions in common stock on August 3, 2026.
Summary
- Grant/award: acquired 73,313 Common Stock on August 3, 2026; holds 542,442 after (Direct).
- Grant/award: acquired 101,428 Stock Option (Right to Buy) on August 3, 2026; holds 101,428 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Christopher James Stevens — Officer (Chief Operating Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-03 | Grant/award | Common Stock | 73,313 | — | — | 542,442 |
| 2026-08-03 | Grant/award | Stock Option (Right to Buy) | 101,428 | — | — | 101,428 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-03 | Grant/award (73,313 shares) |
| 2026-08-03 | Grant/award (101,428 shares) |
Keywords
insider transaction, Form 4, RCKT, ROCKET PHARMACEUTICALS, INC., neutral, Christopher James Stevens
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.